

Robert O'connor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9300804/publications.pdf>

Version: 2024-02-01

35
papers

1,172
citations

361045

20
h-index

377514

34
g-index

37
all docs

37
docs citations

37
times ranked

2397
citing authors

#	ARTICLE	IF	CITATIONS
1	Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 962.	1.8	12
2	Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells. <i>Cancers</i> , 2019, 11, 548.	1.7	19
3	Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles. <i>Scientific Reports</i> , 2017, 7, 44541.	1.6	61
4	Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models. <i>PLoS ONE</i> , 2017, 12, e0177058.	1.1	2
5	Data supporting the shedding of larger extracellular vesicles by multidrug resistant tumour cells. <i>Data in Brief</i> , 2016, 6, 1023-1027.	0.5	9
6	Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016, 1860, 618-627.	1.1	47
7	Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2015, 23, 40.	0.9	21
8	Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a Murine Transverse Aortic Constriction Model. <i>PLoS ONE</i> , 2015, 10, e0140273.	1.1	29
9	A gene expression profile indicative of early stage HER2 targeted therapy response. <i>Molecular Cancer</i> , 2013, 12, 69.	7.9	20
10	The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1357-1368.	1.1	62
11	Stable Aqueous Dispersions of Glycopeptide-Graded Selectably Functionalized Magnetic Nanoparticles. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 3164-3167.	7.2	79
12	Determination Of The Proteomic Response To Lapatinib Treatment Using A Comprehensive And Reproducible Ion-current-based Proteomics Strategy. <i>Journal of Proteomics and Genomics Research</i> , 2013, 1, 27-42.	0.7	2
13	Development, validation and application of a sensitive LC-MS/MS method for the quantification of thalidomide in human serum, cells and cell culture medium. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 902, 16-26.	1.2	11
14	Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines. <i>Molecular Cancer</i> , 2012, 11, 41.	7.9	22
15	The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines. <i>Proteomics</i> , 2012, 12, 2115-2126.	1.3	13
16	Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 56, 785-791.	1.4	22
17	Modulation of P-gp expression by lapatinib. <i>Investigational New Drugs</i> , 2011, 29, 1284-1293.	1.2	16
18	Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. <i>Molecular Cancer</i> , 2011, 10, 126.	7.9	170

#	ARTICLE	IF	CITATIONS
19	A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. <i>Proteomics</i> , 2011, 11, 1391-1402.	1.3	33
20	Challenges of drug resistance in the management of pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1647-1661.	1.1	47
21	Simultaneous determination of anthracyclines and taxanes in human serum using online sample extraction coupled to high performance liquid chromatography with UV detection. <i>Journal of Separation Science</i> , 2010, 33, 1571-1579.	1.3	23
22	Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3982-3990.	1.2	38
23	The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.. <i>Blood</i> , 2009, 114, 1729-1729.	0.6	7
24	Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 521-530.	1.1	25
25	CE-LIF method for the separation of anthracyclines: Application to protein binding analysis in plasma using ultrafiltration. <i>Journal of Separation Science</i> , 2008, 31, 1828-1833.	1.3	27
26	Overexpression of cytochrome P450 NADPH reductase sensitises MDA 231 breast carcinoma cells to 5-fluorouracil: Possible mechanisms involved. <i>Toxicology in Vitro</i> , 2008, 22, 582-588.	1.1	23
27	Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 805-817.	1.5	51
28	Rapid and sensitive liquid chromatography-tandem mass spectrometry for the quantitation of epirubicin and identification of metabolites in biological samples. <i>Talanta</i> , 2007, 72, 145-154.	2.9	32
29	The pharmacology of cancer resistance. <i>Anticancer Research</i> , 2007, 27, 1267-72.	0.5	93
30	Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. <i>International Journal of Cancer</i> , 2004, 111, 484-493.	2.3	35
31	Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. <i>Anticancer Research</i> , 2004, 24, 457-64.	0.5	23
32	Challenges in molecular analysis for individualized cancer therapy. <i>Drug Discovery Today</i> , 2003, 8, 531.	3.2	2
33	Recent developments in drug resistance and apoptosis research. <i>Critical Reviews in Oncology/Hematology</i> , 1998, 28, 181-205.	2.0	15
34	Determination of serum and tissue levels of phenazines including clofazimine. <i>Biomedical Applications</i> , 1996, 681, 307-315.	1.7	14
35	The Pharmacology, Metabolism, and Chemistry of Clofazimine. <i>Drug Metabolism Reviews</i> , 1995, 27, 591-614.	1.5	65